Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Will the drugs destroy the movement for body acceptance
Crucial Quote These phase two data have given us confidence to further explore the potential of retatrutide in phase three trials that will look beyond weight reduction and focus on treating obesity and its complications comprehensively, Dan Skovronsky, ELI Lilly's chief medical and scientific officer, said in a statement
Originally developed for type 2 diabetes treatment, it quickly gained recognition for its ability to aid weight loss
Full peer-reviewed data and detailed statistical analysis haven't been published yet
Dual agonists that target both GLP-1 and GIP receptors provide a more comprehensive metabolic effect than single-receptor medications
US$ 27.18
US$ 28.02
US$ 21.68
US$ 20.76
US$ 24.61
US$ 25.41
